JP2013500329A5 - - Google Patents

Download PDF

Info

Publication number
JP2013500329A5
JP2013500329A5 JP2012522328A JP2012522328A JP2013500329A5 JP 2013500329 A5 JP2013500329 A5 JP 2013500329A5 JP 2012522328 A JP2012522328 A JP 2012522328A JP 2012522328 A JP2012522328 A JP 2012522328A JP 2013500329 A5 JP2013500329 A5 JP 2013500329A5
Authority
JP
Japan
Prior art keywords
antigen
binding
composition
particle
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012522328A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013500329A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2010/053465 external-priority patent/WO2011013097A2/en
Publication of JP2013500329A publication Critical patent/JP2013500329A/ja
Publication of JP2013500329A5 publication Critical patent/JP2013500329A5/ja
Pending legal-status Critical Current

Links

JP2012522328A 2009-07-29 2010-07-29 ポリマー粒子およびその使用 Pending JP2013500329A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US22931809P 2009-07-29 2009-07-29
US22934809P 2009-07-29 2009-07-29
US61/229,318 2009-07-29
US61/229,348 2009-07-29
PCT/IB2010/053465 WO2011013097A2 (en) 2009-07-29 2010-07-29 Polymer particles and uses thereof

Publications (2)

Publication Number Publication Date
JP2013500329A JP2013500329A (ja) 2013-01-07
JP2013500329A5 true JP2013500329A5 (cg-RX-API-DMAC7.html) 2013-09-05

Family

ID=43529777

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012522328A Pending JP2013500329A (ja) 2009-07-29 2010-07-29 ポリマー粒子およびその使用

Country Status (11)

Country Link
US (3) US20120201846A1 (cg-RX-API-DMAC7.html)
EP (1) EP2461822A4 (cg-RX-API-DMAC7.html)
JP (1) JP2013500329A (cg-RX-API-DMAC7.html)
KR (1) KR20140015127A (cg-RX-API-DMAC7.html)
CN (2) CN102573891B (cg-RX-API-DMAC7.html)
AU (1) AU2010277222A1 (cg-RX-API-DMAC7.html)
CA (1) CA2769645A1 (cg-RX-API-DMAC7.html)
EA (1) EA201290072A1 (cg-RX-API-DMAC7.html)
SG (1) SG178144A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011013097A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201201482B (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102180974B (zh) * 2011-03-22 2013-12-11 兰州大学 一种结核杆菌融合蛋白及其制备方法和应用
WO2013158061A1 (en) * 2012-04-16 2013-10-24 Aeras Global Tb Vaccine Foundation Recombinant mycobacterium encoding a heparin-binding hemagglutinin (hbha) fusion protein and uses thereof
WO2013190453A2 (en) * 2012-06-18 2013-12-27 Tracy Thompson Compositions for separation methods
CN102716474B (zh) * 2012-06-27 2013-10-16 中国人民解放军军事医学科学院微生物流行病研究所 蛋白Rh054_01780在抗黑龙江立克次体的免疫保护中的应用
US20150265695A1 (en) * 2012-07-24 2015-09-24 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
US20140073022A1 (en) * 2012-09-10 2014-03-13 Wisconsin Alumni Research Foundation Production of polyhydroxyalkanoates with a defined composition from an unrelated carbon source
US10501505B2 (en) * 2014-02-04 2019-12-10 Bernd Helmut Adam Rehm Polymer particles and uses thereof
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
US11289320B2 (en) 2015-03-06 2022-03-29 Micromass Uk Limited Tissue analysis by mass spectrometry or ion mobility spectrometry
US11282688B2 (en) 2015-03-06 2022-03-22 Micromass Uk Limited Spectrometric analysis of microbes
WO2016142674A1 (en) 2015-03-06 2016-09-15 Micromass Uk Limited Cell population analysis
WO2016142693A1 (en) 2015-03-06 2016-09-15 Micromass Uk Limited In vivo endoscopic tissue identification tool
CA2981085A1 (en) 2015-03-06 2016-09-15 Micromass Uk Limited Spectrometric analysis
EP3570315B1 (en) * 2015-03-06 2024-01-31 Micromass UK Limited Rapid evaporative ionisation mass spectrometry ("reims") and desorption electrospray ionisation mass spectrometry ("desi-ms") analysis of biopsy samples
EP3265823B1 (en) 2015-03-06 2020-05-06 Micromass UK Limited Ambient ionization mass spectrometry imaging platform for direct mapping from bulk tissue
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
WO2017178833A1 (en) 2016-04-14 2017-10-19 Micromass Uk Limited Spectrometric analysis of plants
WO2018053294A1 (en) * 2016-09-16 2018-03-22 Infectious Disease Research Institute Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
JP7313345B2 (ja) 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物
KR102107519B1 (ko) * 2018-06-25 2020-05-07 경상대학교산학협력단 브루셀라 어보투스 균주 유래의 InpB, Dps, AspC 및 Ndk 단백질을 유효성분으로 포함하는 브루셀라 감염증 예방 또는 치료용 백신 조성물
KR102317403B1 (ko) * 2019-01-28 2021-10-29 주식회사 바이오앱 당화된 Ag85A 단백질을 포함하는 결핵 예방용 백신 조성물 및 이의 제조방법
CN109813884A (zh) * 2019-03-25 2019-05-28 中国动物卫生与流行病学中心 一种牛结核病γ-干扰素快速检测制品
CN110411907B (zh) * 2019-06-19 2020-05-22 上海交通大学 植物叶片上亚微米颗粒物凝并效率测定方法、系统及介质
GB201913716D0 (en) * 2019-09-24 2019-11-06 Imp College Innovations Ltd Methods
CN113663063B (zh) * 2020-05-15 2026-05-01 上海市公共卫生临床中心 登革病毒的修饰性mRNA疫苗
JP7584763B2 (ja) * 2020-06-04 2024-11-18 東亞合成株式会社 抗ウイルス性ペプチドおよびその利用
CN117430664B (zh) * 2023-10-24 2024-04-09 暨南大学附属第六医院(东莞市东部中心医院) 一种甲型流感病毒t细胞抗原表位肽及其应用
CN118085043B (zh) * 2024-04-17 2024-07-19 成都康华生物制品股份有限公司 结核分枝杆菌多免疫原抗原、编码其的多核苷酸、应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
EP0175261B1 (en) * 1984-09-12 1991-12-11 Chiron Corporation Hybrid particle immunogens
US6982085B2 (en) * 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
JP4172598B2 (ja) * 1997-04-02 2008-10-29 スタテンス セールム インスティトゥート 結核菌由来の核酸フラグメント及びポリペプチドフラグメント
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
WO2004006952A2 (en) * 2002-07-13 2004-01-22 Statens Serum Institut Therapeutic tuberculosis vaccines
DE10240035A1 (de) * 2002-08-30 2004-03-11 Rehm, Bernd H.A., PD Dr.rer.nat. Biogene Polyester-Partikel definierter Größe mit funktionalisierten Oberflächen:Herstellungsverfahren und pharmazeutische Zubereitungen, in denen diese enthalten sind
ES2596553T3 (es) * 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
US7968105B2 (en) * 2005-06-23 2011-06-28 Statens Serum Institut Tuberculosis vaccines comprising antigens expressed during the latent infection phase
AU2006295515A1 (en) * 2005-09-27 2007-04-05 Polybatics Limited Polymer particles and uses thereof
CN100518821C (zh) * 2006-09-14 2009-07-29 复旦大学 Ag85B,ESAT-6的嵌合疫苗

Similar Documents

Publication Publication Date Title
Coler et al. The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial
Zhu et al. Tuberculosis vaccines: Opportunities and challenges
Andersen TB vaccines: progress and problems
Gupta et al. Current status of TB vaccines
Xin et al. Subunit vaccine consisting of multi-stage antigens has high protective efficacy against Mycobacterium tuberculosis infection in mice
Orme Vaccine development for tuberculosis: current progress
Andersen et al. Novel vaccination strategies against tuberculosis
Skeiky et al. Advances in tuberculosis vaccine strategies
AU2011209399B2 (en) Modified tuberculosis antigens
Whelan et al. Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A
DK2421557T3 (en) TB TUBERCULOSE VACCINE FOR PREVENTION PREVENTION
Geluk et al. A multistage-polyepitope vaccine protects against Mycobacterium tuberculosis infection in HLA-DR3 transgenic mice
US20080311159A1 (en) Methods and Means for Diagnostics, Prevention and Treatment of Mycobacterium Infections and Tuberculosis Disease
Haile et al. Recent developments in tuberculosis vaccines
An et al. Tuberculosis vaccines and therapeutic drug: challenges and future directions
Méndez‐Samperio Development of tuberculosis vaccines in clinical trials: Current status
JP2012524733A5 (cg-RX-API-DMAC7.html)
Hawkridge et al. Prospects for a new, safer and more effective TB vaccine
Ginsberg et al. TB vaccines in clinical development
Husain et al. Current perspective in tuberculosis vaccine development for high TB endemic regions
Safar et al. COVID-19 vaccine development: What lessons can we learn from TB?
Mustafa Early secreted antigenic target of 6 kda-like proteins of mycobacterium tuberculosis: diagnostic and vaccine relevance
JP2003519668A5 (cg-RX-API-DMAC7.html)
Lu et al. Immunogenicity and protective efficacy against murine tuberculosis of a prime‐boost regimen with BCG and a DNA vaccine expressing ESAT‐6 and Ag85A fusion protein
Velayutham Overview of the tuberculosis vaccine development landscape